Meeting
2013 ASCO Annual Meeting
High-dose methotrexate with and without rituximab for the treatment of newly diagnosed primary CNS lymphoma: Johns Hopkins Hospital experience.
Authors
Matthias Holdhoff
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD
Matthias Holdhoff , Guneet Sarai , Ahmed Abdelaziz , David Bonekamp , Stuart A. Grossman , Xiaobu Ye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2034)
DOI
10.1200/jco.2013.31.15_suppl.2034
Abstract #
2034
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
First Author: Marion Alcantara
Poster
2021 ASCO Annual Meeting
Predictive value of lymphocyte immunophenotyping (LIP) in primary central nervous system lymphoma (PCNSL).
First Author: Axel Berthelot
Poster
2020 ASCO Virtual Scientific Program
Ibrutinib-based combination therapy exhibited therapeutic benefit in newly diagnosed primary central nervous system lymphoma.
First Author: Feili Chen
Poster
2020 ASCO Virtual Scientific Program
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.
First Author: Tracy Batchelor